prednisone

P1/2, N=1200, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

Patients received treatment according to the institutional protocols in the form of RCHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone] and RDHAP [rituximab, dexamethasone, high dose cytarabine and cisplatin] as induction therapy and ICE [ifosfamide, carboplatin, etoposide], ESHAP [etoposide, methylprednisolone, high dose cytarabine and cisplatin], gemcitabine-based protocols, and others as second line therapies. To overcome the limitations in our study, larger cohorts are needed to be studied with the evaluation of the novel therapies when feasible. Enhancing financial support is crucial to improve MCL patients' care in our country.

P2, N=31, Not yet recruiting, Fox Chase Cancer Center

P2/3, N=960, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting

P1, N=10, Recruiting, The University of Texas Health Science Center at San Antonio | Trial completion date: Jul 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Oct 2026

The patient was treated with brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone, following which the febrile episodes improved. This case illustrates an uncommon gastrointestinal-predominant presentation of ALK-negative systemic ALCL presenting as fever of unknown origin. This case underscores the importance of continued diagnostic reassessment and symptom-guided tissue acquisition when conventional staging studies are not initially diagnostic, particularly in patients with a history of indolent lymphoma.

The patient received 4 cycles of an attenuated R-THP-COP regimen (rituximab, pirarubicin [tetrahydropyranyl adriamycin, THP, substituted for doxorubicin to reduce cardiotoxicity], cyclophosphamide, vincristine and prednisone). In this single elderly patient, an attenuated R-THP-COP regimen was well tolerated and produced a sustained complete clinical response, suggesting that an individualised, biopsy-guided, chemotherapy-based approach may be a reasonable option for similarly localised disease in elderly patients; this observation, however, requires confirmation in larger series. This case enriches the clinical data of this rare disease and provides a reference for clinical diagnosis and treatment.

P4, N=30, Not yet recruiting, Peking University People's Hospital | N=118 --> 30

P2, N=96, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed

P2, N=60, Not yet recruiting, Beth Israel Deaconess Medical Center

Systemic chemotherapy with vinblastine and prednisone led to marked improvement in nail, skin, pulmonary, and osseous lesions. These cases illustrate that nail changes may be the earliest manifestation of LCH and should prompt thorough systemic evaluation. Early recognition of nail involvement can facilitate timely diagnosis and risk-adapted treatment, potentially improving outcomes in affected patients.

The patient was started on rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with a good clinical response. Diagnosis was delayed due to the significant procedural barriers as a result of her small stature and microcephaly associated with her Angelman syndrome. Prompt multidisciplinary evaluation and alternative tissue acquisition were essential for diagnosis and treatment.